webinar register page

Webinar banner
Meet IGX-Track: Our unique new App for seamless analysis of antibody display data
Display technologies are used to discover antibodies by screening millions of candidates against potential targets. Panning experiments generate vast amounts of sequencing data when coupled with NGS. With the added complexity of different panning conditions (e.g., target, counter-target, control), performing enrichment analyses quickly becomes a daunting task.

Our latest IGX Platform App - IGX-Track - provides a flexible, intuitive, and visual environment that makes it easy to compose any analysis workflow that matches the experimental design of your panning campaign and, ultimately, to select the best antibody candidates.

Join Lorenzo Fanchi, Product Management Team Lead at ENPICOM, for an in-depth discussion on how IGX-Track can help you analyze antibody display data in an intuitive and visual way, by enabling you to easily perform multi-dataset comparisons and identify a diverse set of enriched candidates with the best characteristics.

Attend this webinar to discover how you can:
– Track clones across panning rounds through tabular views and interactive visualizations
– Simplify complex comparative analysis
– Broaden your analysis beyond just the most frequent clones
– Maximize your selection precision by subtracting irrelevant antibodies

Get all these insights and more with this 45-minute session followed by a live Q&A.


Webinar logo
* Required information


Lorenzo Fanchi
Product Management Team Lead @ENPICOM
As Product Management Team Lead at ENPICOM, Lorenzo is responsible for the ongoing development of the IGX Platform, both by improving current apps and functionality, as well as by developing completely novel solutions to address new markets. He manages all phases of product development: from product discovery, envisioning, and prototyping solutions to guiding development and implementation. During his Ph.D. at the Netherlands Cancer Institute, Lorenzo worked on a variety of projects ranging from in vitro and in vivo work, where he explored approaches to improve adoptive cell therapy of cancer, to in silico projects which assessed the immunological foreignness of human cancers.